CTOs on the Move

Bolt Biotherapeutics

www.boltbio.com

 
Bolt Biotherapeutics is a start-up with compelling technology from Dr. Engleman`s Lab at Stanford University, which demonstrated complete cures in numerous cancer models.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Bolt Biotherapeutics raised $54M on 02/07/2019
Bolt Biotherapeutics raised $93.5M on 07/01/2020
Bolt Biotherapeutics raised $15M on 06/07/2021

Similar Companies

Novavax

Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company’s proprietary virus-like-particle (VLP) technology and single-use bioprocessing system enable rapid vaccine development and production where and when they are needed, worldwide. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company’s website

Carterra

Carterra, formerly Wasatch Microfluidics, develops high throughput surface plasmon resonance array-based platforms for biomolecular interaction analysis.

Amira Pharmaceuticals

Amira Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Keryx

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a team of approximately 200 committed people working with passion to identify meaningful new medicines to advance the care of people with kidney disease. We have assembled a deep concentration of kidney care experts, including nephrologists, renal dietitians, nurses and industry veterans in nephrology. Together, we strive to raise awareness of the kidney disease epidemic, give voice to this underserved population, and help healthcare professionals to improve the care of their patients. In September 2014, the U.S. Food and Drug Administration approved Keryx`s first medicine, Auryxia® (ferric citrate) tablets. Keryx established its corporate headquarters in Boston`s innovation district to support the U.S. launch of Auryxia. Patients have been and continue to be at the center of our nearly 20 year corporate history.

Sellas Life Sciences

Sellas Life Sciences is a healthcare-oriented global group of companies with a unique and innovative vision, which is ambitious, yet clear: to practice the medicine of tomorrow, today. In other words, we incorporate innovation throughout all our activities aiming at breakthroughs that will have a significant impact on the thinking and practicing of healthcare worldwide. Our international team of acknowledged scientists, doctors and health professionals along with a seasoned and highly experienced pharmaceutical executive management form the core of Σellas. We strive to improve patients` quality of life through developing and commercializing cutting-edge drugs, medical devices and innovative therapies.